Interaction of the growth hormone releasing peptide hexarelin with somatostatin

What Was Tested

This controlled clinical trial paper looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and Somatostatin.

Growth hormone releasing peptides (GHRPs) are potent growth hormone (GH) secretagogues.

Data on their interaction with somatostatin (SS) are limited.

The aim of this study was to determine the effect of changing SS tone and the effects of SS withdrawal on the somatotroph response to hexarelin and GHRH, alone or in combination.

Who Took Part

PubMed indexes the participants as adults, men only.

How the Study Was Run

The design is described as randomized.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

In a second group of studies, the same boluses as above were administered intravenously at the time of withdrawal of a 3-hour constant intravenous infusion of saline or SS20.

Studies were performed in a random order.

Serum GH and PRL concentrations were measured by immunoradiometric assays.

Serum cortisol concentrations were measured by radioimmunoassay.

What Was Measured

PubMed files the paper under topics including Drug Synergism, Growth Hormone, Hydrocortisone, Immunoradiometric Assay, Oligopeptides, Prolactin and Radioimmunoassay.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and Somatostatin.

Results are reported in around 12 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1997 (Clinical endocrinology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the Somatostatin compound page, all human trials.